Bulion et al. tested the anti-tumor activity of plant-derived bispecific monoclonal antibodies targeting programmed cell death protein 1 (PD-L1) and CTLA-4 in vivo using humanized BALB/c mice carrying CT26 colorectal tumors, demonstrating a reduction in tumor volume and weight, which validates this treatment approach [121]. Here, CTLA4 is linked to neoplasm.